Publications

    Articles

    Last update: February 2020

  1. Tavukcuoglu E, Horzum U, Yilmaz KB, Esendagli G, PD-L2+ wound zone macrophage-like cells display M1/M2-mixed activation and restrain the effector Th1 responses. Immunol Cell Biol. 2019 Dec 16. doi: 10.1111/imcb.12310. [Epub ahead of print] PMID:31845380
  2. Winklmeier S, Schlüter M, Spadaro M, Thaler FS, Vural A, Gerhards R, Macrini C, Mader S, Kurne A, Inan B, Karabudak R, Özbay FG, Esendagli G, Hohlfeld R, Kümpfel T, Meinl E., Kösemehmetoğlu K, Baykal A., Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019 Oct 14;6(6):625. doi: 10.1212/NXI.0000000000000625. Print 2019 Nov. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2019 Nov 15;7(1):. PMID:31611268
  3. Erol T, İmamoğlu NE, Aydin B, Taşkiran ZE, Esendagli G, Kösemehmetoğlu K, Baykal A., Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival. Medicine (Baltimore). 2019 Aug;98(33):e16773. doi: 10.1097/MD.0000000000016773. PMID:31415379
  4. Yoyen-Ermis D, Tunali G, Tavukcuoglu E, Horzum U, Ozkazanc D, Sutlu T, Buyukasik Y, Esendagli G, Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.Sci Rep. 2019 Aug 12;9(1):11697. doi: 10.1038/s41598-019-48256-4. PMID:31406210
  5. Taskiran EZ, Sonmez HE, Kosukcu C, Tavukcuoglu E, Yazici G, Esendagli G, Batu ED, Kiper POS, Bilginer Y, Alikasifoglu M, Ozen S., A Novel Missense LIG4 Mutation in a Patient With a Phenotype Mimicking Behçet's Disease. J Clin Immunol. 2019 Jan;39(1):99-105. doi: 10.1007/s10875-018-0587-7. Epub 2019 Jan 8. PMID:30617623
  6. Ozcan M, Esendagli G, Musdal Y, Canpinar H, Bacanlı M, Anlar HG, Esendağlı-Yılmaz G, Beyramzadeh M, Aksoy Y., Dual actions of the antioxidant chlorophyllin, a glutathione transferase P1-1 inhibitor, in tumorigenesis and tumor progression. J Cell Biochem. 2018 Nov 28. doi: 10.1002/jcb.27974. PMID:30484884
  7. Kopru CZ, Cagnan I, Akar I, Esendagli G, Korkusuz P, Gunel-Ozcan A., Dual Effect of Glucocorticoid-Induced Tumor Necrosis Factor-Related Receptor Ligand Carrying Mesenchymal Stromal Cells on Small Cell Lung Cancer: A Preliminary in vitro Study. Cytotherapy. 2018 Jul;20(7):930-940. doi: 10.1016/j.jcyt.2018.05.002. Epub 2018 Jun 28. PMID:30180943
  8. Kara A, Ozturk N, Esendagli G, Ozkose UU, Gulyuz S, Yilmaz O, Telci D, Bozkir A, Vural I., Development of novel self-assembled polymeric micelles from partially hydrolysed poly(2-ethyl-2-oxazoline)-co-PEI-b-PCL block copolymer as non-viral vectors for plasmid DNA in vitro transfection. Artif Cells Nanomed Biotechnol. 2018 Jul 23:1-10. doi: 10.1080/21691401.2018.1491478. PMID:30032650
  9. Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S, How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2018 May 21. doi: 10.1007/s00262-018-2170-8. PMID:29785656
  10. Yoyen-Ermis D, Ozturk-Atar K, Kursunel MA, Aydin C, Ozkazanc D, Gurbuz MU, Uner A, Tulu M, Calis S, Esendagli G, Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody. Mol Pharm. 2018 Apr 2;15(4):1526-1533. doi: 10.1021/acs.molpharmaceut.7b01075. PMID:29481086
  11. Esendagli G, Yoyen-Ermis D, Guseinov E, Aras C, Aydin C, Uner A, Hamaloglu E, Karakoc D., Impact of repeated abdominal surgery on wound healing and myeloid cell dynamics. J Surg Res. 2018 Mar;223:188-197. doi: 10.1016/j.jss.2017.11.030. Epub 2017 Dec 1. PMID:29433873
  12. Sevmis M, Yoyen-Ermis D, Aydin C, Bilgic E, Korkusuz P, Uner A, Hamaloglu E, Esendagli G, Karakoc D, Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis. Immunol Invest. 2017 Oct;46(7):663-676. PMID:28872973
  13. Sahin A, Yoyen-Ermis D, Caban-Toktas S, Horzum U, Aktas Y, Couvreur P, Esendagli G, Capan Y, Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells. J Microencapsul. 2017 Sep 13:1-8. PMID:28862080
  14. Erdoğar N, Esendagli G, Nielsen TT, Esendağlı-Yılmaz G, Yöyen-Ermiş D, Erdoğdu B, Sargon MF, Eroğlu H, Bilensoy E. Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer. J Drug Target. 2018 Jan;26(1):66-74. Epub 2017 Jun 25. PMID:28581827
  15. Kursunel MA, Esendagli G. Corrigendum to "The untold story of IFN-γ in cancer biology". 31 (2016) 73-8,Cytokine Growth Factor Rev. 2017 Jun;35:97. PMID:28258821
  16. Kursunel MA, Esendagli G. Corrigendum to "The untold story of IFN-γ in cancer biology". 31 (2016) 73-8,Cytokine Growth Factor Rev. 2017 Jun;35:97. PMID:28258821
  17. Sahin A, Esendagli G, Yerlikaya F, Caban-Toktas S, Yoyen-Ermis D, Horzum U, Aktas Y, Khan M, Couvreur P, Capan Y. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery.Artif Cells Nanomed Biotechnol. 2017 Jan 13:1-11. PMID:28084837
  18. Öztürk K, Esendagli G, Gürbüz MU, Tülü M, Çalış S. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.Int J Pharm. 2017 Jan 30;517(1-2):157-167. Epub 2016 Dec 10. PMID:27965135
  19. Ozkazanc D, Yoyen-Ermis D, Tavukcuoglu E, Buyukasik Y, Esendagli G.Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells.Immunology. 2016 Dec;149(4):460-471. PMID:27565576
  20. Gürbüz MU, Öztürk K, Ertürk AS, Yoyen-Ermis D, Esendagli G, Çalış S, Tülü M1.Cytotoxicity and biodistribution studies on PEGylated EDA and PEG cored PAMAM dendrimers J Biomater Sci Polym Ed. 2016 Nov;27(16):1645-58. PMID:27534577
  21. Erdoğar N, Esendagli G, Nielsen TT, Şen M, Öner L, Bilensoy E. Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles. nt J Pharm. 2016 Jul 25;509(1-2):375-390. Epub 2016 Jun 6. PMID:27282534
  22. Sarmadi P, Tunali G, Esendagli-Yilmaz G, Yilmaz KB, Esendagli, G. CRAM-A indicates IFN-γ-associated inflammatory response in breast cancer. MolImmunol. 2015 Dec;68(2 Pt C):692-8. PMID:26563945
  23. Unver N, Esendagli G, Yilmaz G, Guc D. CXCL7-induced macrophage infiltration in lung tumor is independent of CXCR2 expression: CXCL7-induced macrophage chemotaxis in LLC tumors. Cytokine. 2015 Oct;75(2):330-7. PMID:25732602
  24. Kilic AK, Esendagli G, Sayat G, Talim B, Karabudak R, Kurne AT. Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes' stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide. Autoimmunity. 2015;48(6):423-8. PMID:25826286
  25. Dolen Y, Gunaydin G, Esendagli G, Guc D. Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma. Cell Immunol. 2015 May;295(1):29-35. PMID:25732602
  26. Turhan N, Esendagli, G, Ozkayar O, Tunali G, Sokmensuer C, Abbasoglu O. Co-existence of Echinococcus granulosus infectionand cancer metastasis in the liver correlates with reduced Th1 immune responses. ParasiteImmunol. 2015 Jan;37(1):16-22. PMID:25319434
  27. Sengel-Turk CT, Hascicek C, Dogan AL, Esendagli, G. Guc D, Gonul N. Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line. Journal of Drug Delivery Science and Technology. 2014;24(2):166-172.
  28. Karasar P, Esendagli G, T helper response saremaintainedbybasal-like breast cancer cell sand confertoimmunemodulationvia upregulation of PD-1 ligands. BreastCancerResTreat. 2014 Jun;145(3):605-14. PMID:24816762
  29. Rama-Esendagli D, Esendagli G, Yilmaz G, Guc D. Spheroid formation and invasion capacity are differentially in fluencedbyco-cultures of fibroblast and macrophagecells in breastcancer. MolBiolRep. 2014 May;41(5):2885-92. PMID:24469725
  30. Dolen Y, Esendagli G, Myeloidleukemiacellswith a B7-2(+) subpopulation provoke Th-cell responses and become immuno suppressive through the modulation of B7 ligands. Eur J Immunol. 2013 Mar;43(3):747-57. PMID:23175469
  31. Esendagli, G. Kurne AT, Sayat G, Kilic AK, Guc D, Karabudak R. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patient sunder interferon beta-1 therapy. J Neuroimmunol. 2013 Feb 15;255(1-2):81-4. PMID:23177721
  32. Camurdanoglu BZ, Esendagli G, Ozdemir E, Canpinar H, Guc D, Kansu E. Theeffect of granulocytecolonystimulatingfactorreceptor gene missensesinglenucleotidepolymorphisms on peripheralbloodstemcellenrichment. Cytokine. 2013 Feb;61(2):572-7. PMID:23159284
  33. Şengel-Türk CT, Hasçiçek C, Dogan AL, Esendagli G, Guc D, Gönül N. Preparationand in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 humancolonadenocarcinomacells. Drug. Dev. Ind. Pharm. 2012 Sep;38(9):1107-16. PMID:22348284
  34. Mert O, Esendagli G, Dogan AL, Demir AS. Injectable biode gradable polymeric system for preserving the active form anddelayed-release of camptothecinanti cancer drugs. RSC Advances 2012; 2, 176–185.
  35. Rama D, Esendagli G, Guc D. Expression of chemokine-likereceptor 1 (CMKLR1) on J744A.1 macrophagesco-culturedwithfibroblastand/ortumorcells: Modelingtheinfluence of microenvironment. Cellular Immunology 2011; 271(1):134-40. PMID:21752353
  36. Kurne A,Guc D, Canpinar H, Aydin Ö.F, Sayat G, Yörübulut M,Esendagli G, Karabudak R. Analysis of BAFF and TRAIL expressionlevels in multiplesclerosispatients: evaluation of expressionunderimmunomodulatorytherapy. ActaNeurologicaScandinavica 2011 Jan;123(1):8-12. PMID:20456241
  37. Fahmi T, Esendagli G, Yilmaz G, Kansu E, Guc D. Immunecompartmentalization of T cellsubsets in chemically-inducedbreastcancer.ScandinavianJournal of Immunology2010 Oct;72(4):339-48. PMID:20883319
  38. Esendagli G, Canpinar H, Doğan A.L, Akkaya M, Kansu E, Guc D. Transfection efficiency of myeloid leukaemia cells is differentiallyregulatedby fibronectin substratum. Cytotechnology 2009 Dec;61: 45-53. PMID:19967401
  39. Esendagli G, Canpinar H, Yilmaz G, Kaymaz F, Kansu E, Guc D. Fibronectin promotesthephorbol 12-myristate 13-acetate (PMA)-inducedmacrophagedifferentiation in myeloidleukemiacells. International Journal of Hematology2009 Mar;89: 167-172. PMID:19160003
  40. Esendagli G, Canpinar H, Yilmaz G, Gunel-Ozcan A, Guc M.O, Kansu E, Guc D. Primary tumor cells obtained from MNU-inducedmammarycarcinomasshowimmuneheterogeneitywhich can be modulatedbylow-efficiencytransfection of CD40L gene.CancerBiologyandTherapy2009 Jan 27;8(2): 136-142. PMID:19164932
  41. Bilensoy E,Sarisozen C, Esendagli G, Dogan A. L, Aktas Y, Mungan N. A. Intravesical cationic nano particles of chitosanandpolycaprolactoneforthedelivery of mitomycin C tobladdertumors. International Journal of Pharmaceutics, 2009 Apr 17;371(1-2):170-6. PMID:19135514
  42. Esendagli G, Yilmaz G, Canpinar H, Gunel-Ozcan A, Guc M. O, Guc D. Co-existence of differenttissuetumourigenesis in an N-methyl-N-nitrosourea-inducedmammarycarcinoma model: A histopathological report in Sprague-Dawleyrats. Laboratory Animals 2009 Jan;43(1):60-4. PMID:18987061
  43. Esendagli G, Gunel-Ozcan A, Canpinar H, Guc D. Cloningandfunctionalanalysis of a novelpolymorphicvariant of rat (Rattusnorvegicus) CD40 ligand gene. MolecularBiologyReports 2009 Jan;36(1): 83-89. PMID:17922253
  44. Canpinar H, Esendagli G, Kansu E, Gunel-Ozcan A, Guc D. Adhesion of Beta1 integrin to fibronectin regulates CAM-DR phenotypevia p21WAF1/cip1 in HL60 acutemyeloidleukemia (AML) cells. TurkishJournal of MedicalSciences 2008 Apr;38(2): 97-104. PMID:18987061
  45. Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cellsandregulatory T cells in non-smallcelllungcancer. LungCancer2008 Jan;59(1): 32-40. PMID:17825949

Book Chapters

  • Esendagli G,(2013) Treat as a host to investigate tumorimmunology, Chapter 3, in: Treat in cancer research: a crucial tool for all aspects of translational studies, Daniel L. Pouliquen (ed.), Research Signpost, Trivandrum, Kerala, India, ISBN: 978-81-308-0485-9.
  • Esendagli G, Sitokinler ve Kemokinler, Bölüm 4, Temel ve Klinik Nöroimmünoloji kitabında, Rana Karabudak (ed.), ADA Basın Yayın, Ankara, Türkiye, ISBN: 978-605-63678-1-6.
  • A. Kesikli, Esendagli G, E. Kansu. (2007) Tümör İmmünoterapisinde Güncel Kavramlar, “ÜroonkolojiKitabı”nda, Özen H, Türkeri L (ed.), Üroonkoloji Derneği, Ankara, Türkiye, ISBN: 978-975-01697-0-0.